Pharmacokinetics and clearance processes of UK-279,276 (rNIF) in rat and dog: Comparison with human data

Xenobiotica

Volumn 36, Issue 4, 2006, Pages 341-349

  Webster, R ^a   Edgington, A ^a   Phipps, J ^a   Walker, D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Asialoglycoprotein receptor; CD11b; Glycoprotein; Neutrophil inhibitor factor; Pharmacokinetics; Species difference; UK 279,276

Indexed keywords

CD11B ANTIGEN; NEUTROPHIL INHIBITORY FACTOR; RECOMBINANT NEUTROPHIL INHIBITORY FACTOR; RECOMBINANT PROTEIN; UK 279 276; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CELL ADHESION; DISTRIBUTION VOLUME; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; IC 50; LINEAR SYSTEM; MALE; NEUTROPHIL; NONHUMAN; RAT; RECEPTOR BINDING; SPECIES COMPARISON; SPECIES DIFFERENCE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD11B; AREA UNDER CURVE; ASIALOGLYCOPROTEIN RECEPTOR; DOGS; GLYCOPROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; MALE; RATS; RATS, INBRED F344; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 33646764175     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600630941     Document Type: Article

References (12)

1. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. 1999. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. Journal of Pharmacokinetics and Biopharmacology 27:397-420.
2. Bowen JD, Petersdorf SH, Richards TL, Maravilla KR, Dale DC, Price TH, St John TP, Yu AS. 1998. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clinical Pharmacology and Therapy 64:339-346.
3. Jiang N, Chopp M, Chahwala S. 1998. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Research 788:25-34.
4. Jiang N, Moyle M, Soule HR, Rote WE, Chopp M. 1995. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Annals of Neurology 38:935-942.
5. Jonsson EFM, James I, Wild W, Larlsson M, Marshall S. 2001. Population pharmacokinetic/pharmacodynamic (PK/PD) of UK-279,276 (NIF) in healthy male volunteers and patients. Clinical Pharmacology and Therapeutics 69:P54.
6. Mahmood I, Balian JD. 1999. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clinical Pharmacokinetics 36:1-11.
7. Moyle M, Foster DL, McGrath DE, Brown SM, Laroche Y, De Meutter J, Stanssens P, Bogowitz CA, Fried VA, Ely JA, Soule HR, Vlasuk GP. 1994. A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. Journal of Biology and Chemistry 269:10008-10015.
8. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. 1993. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): A nonplasmin fibrinolytic pathway. Blood 82:2414-2422.
9. Walzog B, Gaehtgens P. 2000. Adhesion molecules: The path to a new understanding of acute inflammation. News in the Physiology Sciences 15:107-113.
10. Webster R. 2000. Neutrophil inhibitor factor (rNIF): A case study in pharmacokinetics and metabolism. Drug Metabolism Reviews 32:21.
11. Webster R, Phipps J, Hyland R, Walker D. 2003. Evaluation of the role of the asialoglycoprotein receptor in the clearance of UK-279,276 (recombinant neutrophil inhibitory factor). Xenobiotica 33:945-956.
12. Webster R, Taberner J, Edgington A, Guhan S, Varghese J, Feeney H, Blocker L, Jezequel SG. 1999. Role of sialylation in determining the pharmacokinetics of neutrophil inhibitory factor (NIF) in the Fischer 344 rat. Xenobiotica 29:1141-1155.